The biotech newsletter has announced its final edition of 2023 and will resume on January 3. The newsletter covers key updates in biotech, including Bristol Myers Squibb’s purchase of Karuna Therapeutics and the FDA approval of a new medicine for a rare nerve disease. The biotech sector is experiencing volatility, with the XBI biotech index having its worst day since February followed by a recovery. Cytokinetics is expected to release Phase 3 data for its drug, aficamten, by late December. Additionally, the pharmaceutical industry has faced challenges in developing treatments for post-traumatic stress disorder.
Source link
Bristol Myers Squibb, Allovir, Sarepta
